The Active Cancer Immunotherapy OBI-822, has been granted by COFEPRIS of Mexico to proceed to Phase III Human Clinical Study
2021.Nov.30
Announcement on behalf of subsidiary, OBIGEN, that OBI-858 completes its Phase I and demonstrates good safety, proceeding to Phase II as planned
2021.Nov.26
OBI’s BOD resolved to in-license a preclinical project from a biotech company specialized in novel cancer therapies
2021.Nov.26
Announcement of the resolution of the Board of Directors of the Company to issue common shares through cash capital increase
2021.Nov.12
Supplementary statements on news article
2021.Nov.11
Intellectual property rights licensing of OBI’s cancer therapies in China has been granted by MOEAIC
2021.Nov.05
Announcement of amendment of the regulations for issuance and subscription of 2021 employee stock options
2021.Nov.05
Announcement of the Consolidated Financial Statements for the third quarter of 2021 were authorized for issuance by the Board of Directors
2021.Nov.03
OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
2021.Oct.27
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of Re-election of directors and supervisors at the 2021 annual shareholders’ meeting
